Assertio Therapeutics Common Stock Total Equity Over Time
| ASRT Stock | USD 0.98 0.03 2.97% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Assertio Therapeutics Performance and Assertio Therapeutics Correlation. Assertio |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Assertio Therapeutics. If investors know Assertio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Assertio Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.19) | Earnings Share (4.94) | Revenue Per Share 1.322 | Quarterly Revenue Growth (0.18) | Return On Assets (0.01) |
The market value of Assertio Therapeutics is measured differently than its book value, which is the value of Assertio that is recorded on the company's balance sheet. Investors also form their own opinion of Assertio Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Assertio Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Assertio Therapeutics' market value can be influenced by many factors that don't directly affect Assertio Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Assertio Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Assertio Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Assertio Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Common Stock Total Equity Analysis
Compare Assertio Therapeutics and related stocks such as Agile Thrpe, Amneal Pharmaceuticals,, and AcelRx Pharmaceuticals Common Stock Total Equity Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMRX | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 | 3 M | 3 M | 3 M | 3 M | 3 M | 3.5 M | 2.8 M |
| IRWD | 7 K | 101 K | 108 K | 121 K | 141 K | 143 K | 148 K | 151 K | 154 K | 158 K | 161 K | 162 K | 154 K | 177.1 K | 125.3 K |
| NBIX | 25 K | 55 K | 66 K | 67 K | 76 K | 86 K | 87 K | 89 K | 91 K | 92 K | 100 K | 100 K | 100 K | 115 K | 67.8 K |
| ESPR | 1.9 K | 308 | 346 | 15.4 K | 20 K | 23 K | 23 K | 26 K | 27 K | 27 K | 26 K | 61 K | 75 K | 86.2 K | 90.6 K |
| ANIP | 13.4 M | 255.1 M | 273.1 M | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 | 900 | 855 |
| ALKS | 207.2 K | 1.3 M | 1.3 M | 1.4 M | 1.5 M | 1.5 M | 1.5 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.7 M | 1.7 M | 1.9 M | 1.2 M |
| RDY | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 830 M | 830 M | 831 M | 832 M | 832 M | 832 M | 956.8 M | 522.2 M |
| COLL | 1000 | 1000 | 1000 | 1000 | 8 K | 21 K | 29 K | 33 K | 33 K | 34 K | 35 K | 36 K | 37 K | 42.5 K | 29.4 K |
| PCRX | 1000 | 25 K | 33 K | 34 K | 36 K | 37 K | 37 K | 41 K | 41 K | 42 K | 44 K | 45 K | 45 K | 51.8 K | 32.8 K |
| ITCI | 1.5 K | 1.5 K | 1.5 K | 500 | 3 K | 4.3 K | 4.3 K | 5.5 K | 5.5 K | 5.6 K | 8 K | 8.2 K | 9 K | 10.3 K | 5.5 K |
| CTLT | 700 K | 700 K | 700 K | 700 K | 1.2 M | 1.2 M | 1.3 M | 1.3 M | 1.5 M | 1.6 M | 2 M | 2 M | 2 M | 2.3 M | 1.5 M |
| AMPH | 4 K | 4 K | 4 K | 4 K | 4 K | 5 K | 5 K | 5 K | 5 K | 5 K | 5 K | 6 K | 6 K | 6.9 K | 5.4 K |
| EOLS | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 | 900 | 800 |
Assertio Therapeutics and related stocks such as Agile Thrpe, Amneal Pharmaceuticals,, and AcelRx Pharmaceuticals Common Stock Total Equity description
The total value of common stock equity held by shareholders, representing their ownership interest in the company.My Equities
My Current Equities and Potential Positions
| Assertio Therapeutics | ASRT |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Illinois; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.98
Additional Tools for Assertio Stock Analysis
When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.